Clinical Reviews and Opinions
Subscribe to CRO
Full Name*
Email Address*

Article Number - 388202456910


Vol.7(1), pp. 1-10 , January 2016
DOI: 10.5897/CRO15.0098
ISSN: 2141-2553



Review

Impact of seasonal malaria chemoprevention of sulphadoxine–pyrimethamine plus amodiaquine on molecular markers resistance of Plasmodium falciparum malaria: A review in West Africa



Hamma Maiga
  • Hamma Maiga
  • Molecular Epidemiological and Drug Resistance Unit, Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology of Bamako. MALI, West Africa.
  • Google Scholar







 Received: 08 October 2015  Published: 30 January 2016

Copyright © 2016 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


The study discuss the potential impact of seasonal malaria chemoprevention (SMC) on the cases of malaria, anaemia and molecular markers resistance Plasmodium falciparum malaria; and also review the mechanism of action and the effect on immunity of SMC. SMC using an efficacious drug is likely to substantially reduce cases of clinical malaria in high transmission settings. However, an increase of molecular markers could hamper rolling out SMC as a national policy.
 
Key words: Seasonal malaria chemoprevention impact, malaria molecular markers, review.
 

Alker AP, Kazadi WM, Kutelemeni AK, Bloland PB, Tshefu AK, Meshnick SR (2008). dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health 13(11):1384-91.
Crossref

 

Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, Tanner M, Alonso PL (2007). Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 4:1259-67.

 
 

Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P (2003). DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J. Antimicrob. Chemother. 52(1):43-9.
Crossref

 
 

Barger B, Maiga H, Traore OB, Tekete M, Tembine I, Dara A, Traore ZI, Gantt S, Doumbo OK, Djimde AA (2009). Intermittent Preventive Treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop. Med. Int. Health 14(7):784-91.
Crossref

 
 

Beier JC, Killeen GF, Githure JI (1999). Short report: Entomologic inoculation rates and Plasmodium falciparum malaria prevalence in Africa. Am. J. Trop. Med. Hyg. 61(1):109-13.

 
 

Berglez J, Iliades P, Sirawaraporn W, Coloe P, Macreadie I (2004). Analysis in Escherichia coli of Plasmodium falciparum dihydropteroate synthase (DHPS) alleles implicated in resistance to sulfadoxine. Int. J. Parasitol. 34(1):95-100.
Crossref

 
 

Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B (2010). A randomized trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One. 5:e11225.
Crossref

 
 

Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, Conway DJ, Jasseh M, Wiseman V, Milligan PJ, Greenwood B (2011). Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomized controlled trial. PLoS Med. 8(2):e1000409.
Crossref

 
 

Bruce-Chwatt LJ (1980). Essential malariology, vol. 354. William Heinemann Medical Books Ltd., London, United Kingdom.

 
 

Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, Greenwood B, Chandramohan D (2008). Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS One. 3(5):e2227.
Crossref

 
 

Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, Ghani AC, Greenwood BM (2012). Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat. Commun. 3:881.
Crossref

 
 

Chandramohan D, Owusu-Agyei S, Carneiro I, Awinw T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B (2005). Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 331(7519):727-33.
Crossref

 
 

Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, Carneiro I (2007). Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop. Med. Int. Health 12(6):743-50.
Crossref

 
 

Cissé B, Sokhna C, Boulanger D, Milet J, Bâ el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF (2006). Seasonal intermittent preventive treatment with artesunate and sulfadoxine–pyrimethamine for prevention of malaria in Senegalese children: a randomized, placebo-controlled, double-blind trial. Lancet 367:659-67.
Crossref

 
 

Clarke SE, Jukes MC, Njagi JK, Khasakhala L, Cundiill B, Otido J, Crudder C, Estambale BB, Brooker S (2008). Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomised, double-blind, placebo- controlled trial. Lancet 372:127-38.
Crossref

 
 

Dicko A, Barry A, Dicko M, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Conaré T, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B (2011). Malaria Morbidity in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria in Mali: A Randomized Control Trial. PLoS One. 6(8):e23390.
Crossref

 
 

Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo AI, Kone M, Toure OB, Sacko M, Doumbo OK (2008). Impact of intermittent preventive treatment with sulphadoxine–pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar. J. 7:123.
Crossref

 
 

Dieckmann A, Jung A (1986). The mechanism of pyrimethamine resistance in Plasmodium falciparum. Parasitology 93(Pt 2):275-8.
Crossref

 
 

Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O (2007). Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar. J. 6:80. Image
Crossref

 
 

Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, Ndiaye M, Sow D, De Sousa A, Gaye O (2011). Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol. Res. 109(1):133-8.
Crossref

 
 

Foote SJ, Galatis D, Cowman AF (1990). Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA. 87:3014-7.
Crossref

 
 

Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D (2009). Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 313(9700):1521-32.
Crossref

 
 

Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D (2008). Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar. J. 7:54.
Crossref

 
 

Greenwood B (2007). Intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45:26-28.
Crossref

 
 

Grobusch MP, Lell B, Schwarz NG (2007). Intermittent preventive treatment against malaria in infants in Gabon – a randomized, double blind, placebo-controlled trial. J. Infect. Dis. 196:1595-1602.
Crossref

 
 

Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF and Oduola AM (2005). Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 95:183-93.
Crossref

 
 

Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, Abruquah HH, Kreuels B, Ayim M, Busch W, Marks F, Amoah K, Opoku E, Meyer CG, Adjei O, May J (2007). A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin. Infect. Dis. 45(1):16-25.
Crossref

 
 

Konaté AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouedraogo A, Tiono AB, Ouedraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA (2011). Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomized, double blind, and placebo controlled trial. PLoS Med. 8(2):e1000408.
Crossref

 
 

Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 185:380-8.
Crossref

 
 

Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, Chandramohan D (2008). Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE 3(12):e4000.
Crossref

 

 

Lo AC, Faye B, Ba el-H, Cisse B, Tine R, Abiola A, Ndiaye M, Ndiaye JL, Ndiaye D, Sokhna C, Gomis JF, Dieng Y, Faye O, Ndir O, Milligan P, Cairns M, Hallett R, Sutherland C, Gaye O (2013). Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar J. 12:137.
Crossref

 

Macdonald G (1957). The epidemiology and control of malaria. Oxford University Press, London, United Kingdom.

 
 

Marks F, Meyer CG, Sievertsen J, TimmannCEvans J, Horstmann RD, May J (2004). Genotyping of Plasmodium falciparum pyrimethamine resistance by matrix-assisted laser desorption–ionization time-of-flight mass spectrometry. Antimicrob. Agents Chemother. 48(2):466-72.
Crossref

 
 

Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, Mandomando I, Puyol L, Berzosa P, Doba-o C, Aide P, Sacarlal J, Benito A, Alonso P, Menéndez C (2008). Molecular markers of resistance to sulfadoxine–pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J. Infect. Dis. 197(12):1737-42.
Crossref4

 
 

McElroy PD, Beier JC, Oster CN, Onyango FK, Oloo AJ, Lin X, Beadle C, Hoffman SL (1997). Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am. J. Epidemiol. 145(10):945-56.
Crossref

 
 

Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, Ziniel P, Dzisi SY, Frempong M, Agana-Nsiire P, Amoo-Sakyi F, Otchwemah R, Cramer JP, Anemana SD, Dietz E, Bienzle U (2007). Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob. Agents Chemother. 51(9):3273-81.
Crossref

 
 

Molineaux L (1997). Nature's experiment: what implications for malaria prevention? Lancet 349:1636-7.
Crossref

 
 

Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, Nkya W, Kataraihya J, Abdulla S, Beck HP, Mshinda H (2004). Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am. J. Trop. Med. Hyg. 71:696-702.

 
 

Nfor ENMW, Njifutri N, Mbulli IA, Tawé B, Masumbi NP, Venyoka A (2007). Evaluation de la chimiorésistance à la sulfadoxine-pyrimethamine et des mutations des genes dhfr et dhps dans le district de sante de Ndu au nord-ouest Cameroun. Afr. J. Sci. Tech. 8:52-55.Image

 
 

Nzila-Mounda A, Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM (1998). Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob. Agents Chemother. 42:164-9.

 
 

Omar SA, Adagu IS, Warhurst DC (2001). Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans. R. Soc. Trop. Med. Hyg. 95:315-9.
Crossref

 
 

Patil AP, Okiro EA, Gething PW, Guerra CA, Sharma SK, Snow RW and Hay SI (2009). Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation. Malar. J. 8:186.
Crossref

 
 

Quelhas D, Puyol L, Quintó L, Serra-casa E, Nhampossa T, Macete E, Aide P, Mayor A, Mandomando I, Sanz S, Aponte JJ, Chauhan VS, Chitnis CE, Alonso PL, Menéndez C and Doba-o C (2008). Impact of intermittent preventive treatment with sulfadoxine–pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin. Vaccine Immunol. 15(8):1282-91.
Crossref

 
 

Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF (1996). Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg. 55:209-13.

 
 

Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, Stein C, Nahlen BI, Bryce J, Black RE, Steketee RW (2006). The burden of malaria mortality among African children in the year 2000. Int. J. Epidemiol. 35(3):691-704.
Crossref

 
 

Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, Mshinda H, Alonso P (2005). Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365(9469):1481-3.
Crossref

 
 

Schreiber N, Kobbe R, Adjei S, Adjei O, Klinkert MQ, May J (2007). Immune responses after single-dose sulphadoxine–pyrimethamine indicate under- estimation of protective efficacy of intermittent preventive treatment in infants. Trop. Med. Int. Health 12(10):1157-63.
Crossref

 
 

Sesay S, Milligan P, Touray E, Sowe M, Webb EL, Greenwood BM, Bojang KA (2011). A trial of intermittent preventive treatment and home-based management of malaria in a rural area of the Gambia. Malar. J. 10:2.
Crossref

 
 

Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM and Nzila AM (2001). Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17:582-8.
Crossref

 
 

Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV (1997). Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. USA. 94:1124-9.
Crossref

 
 

Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, Weber MW, Pinder M, Nahlen B, Obonyo C, Newbold C, Gupta S, Marsh K (1997). Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349(9066):1650-4.
Crossref

 
 

Sokhna C, Cisse B, Bâ el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF (2008). A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One. 3(1):e1471.
Crossref

 
 

Somé AF, Zongo I, Compaoré YD, Sakandé S, Nosten F, Ouédraogo JB, Rosenthal PJ (2014). Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 58(7):3660-5.
Crossref

 
 

Sutherland CJ, Drakeley CJ, Schellenberg D (2007). How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar. J. 6:161.
Crossref

 
 

Triglia T, Cowman AF (1999). The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist. Updat. 2:15-9.
Crossref

 
 

Vekemans J, Ballou WR (2008). Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines 7(2):223-40.
Crossref

 
 

Wipasa J, Riley EM (2007). The immunological challenges of malaria vaccine development. Expert Opin. Biol. Ther. 7(12):1841-52.
Crossref

 
 

World Health Organization (WHO) (2000). Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl 1):S1-90.
Crossref

 
 

World Health Organization (WHO) (2008). The World Malaria Report 2008. 

View

 
 

World Health Organization (WHO) (2010). Global report on antimalarial drug efficacy and drug resistance 2000-2010. 

View

 
 

World Health Organization (WHO) (2011). The World Malaria Report 2011. 

View

 
 

Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, Rosenthal PJ, Sutherland C, Nosten F, Ouedraogo JB (2015). Randomized Non-inferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 59(8):4387-96.
Crossref

 

 


APA Maiga, H., (2016). Impact of seasonal malaria chemoprevention of sulphadoxine–pyrimethamine plus amodiaquine on molecular markers resistance of Plasmodium falciparum malaria: A review in West Africa. Clinical Reviews and Opinions, 7(1), 1-10.
Chicago Hamma Maiga. "Impact of seasonal malaria chemoprevention of sulphadoxine–pyrimethamine plus amodiaquine on molecular markers resistance of Plasmodium falciparum malaria: A review in West Africa." Clinical Reviews and Opinions 7, no. 1 (2016): 1-10.
MLA Hamma Maiga. "Impact of seasonal malaria chemoprevention of sulphadoxine–pyrimethamine plus amodiaquine on molecular markers resistance of Plasmodium falciparum malaria: A review in West Africa." Clinical Reviews and Opinions 7.1 (2016): 1-10.
   
DOI 10.5897/CRO15.0098
URL http://academicjournals.org/journal/CRO/article-abstract/388202456910

Subscription Form